Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021
Marie C. Bradley, Silvia Pérez-Vilar, Yoganand Chillarige, Diane Dong, Ashley I. Martinez, Andrew R. Weckstein, Gerald J. Dal Pan
Abstract
In June 2020, preliminary results for the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial conducted in the UK indicated benefit from dexamethasone in severely ill hospitalized patients with COVID-19 but potential harm in those not requiring oxygen. 1,2 In October 2020, the National Institutes of Health (NIH) issued COVID-19 treatment guidelines advising against systemic corticosteroid use in patients with mild to moderate COVID-19. 1 Using 2 large US health care claims databases, we examined systemic corticosteroid use among nonhospitalized patients with COVID-19.
Topics & Concepts
MedicineFood and drug administrationCoronavirus disease 2019 (COVID-19)Corticosteroid2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Administration (probate law)Family medicineMedical emergencyVirologyInternal medicineLawInfectious disease (medical specialty)OutbreakPolitical scienceDiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19COVID-19 and healthcare impacts